Skip to content

    Aether Industries Limited

    AETHER
    Chemicals·24 Jul 2025
    Management Summary

    Aether Industries reported a strong Q1 FY26 with significant revenue and profit growth, driven by robust demand in large-scale manufacturing and new contract wins, notably a 10-year agreement with Milliken. Margins expanded considerably, and the company made progress in reducing its working capital cycle. Strategic capex plans for R&D and new sites are on track, positioning for future growth, despite some headwinds in the electrolyte additives segment.

    Highlights

    7
    • Total consolidated revenue grew 35% YoY to ₹2,587 million in Q1 FY26 from ₹1,920 million in Q1 FY25.

    • EBITDA increased 94% YoY to ₹781 million in Q1 FY26 from ₹402 million in Q1 FY25, with EBITDA margin expanding to 30% from 22%.

    • PAT grew 57% YoY to ₹470 million in Q1 FY26 from ₹299 million in Q1 FY25, with PAT margin at 18% (vs 16% in Q1 FY25).

    • Demand for large-scale manufacturing (LSM) products grew 9% YoY and 8% QoQ, with 6 new clients added.

    • Executed a 10-year contract manufacturing agreement with Milliken Chemical & Textile India, dedicating new Site 3+ for this strategic product.

    • Working capital cycle reduced to 190 days (from 195 days) and inventory days to 165 (from 175 days).

    • R&D facilities expansion planned with ₹30-40 crores capex, increasing labs from 15 to 18 and fume hoods from 65 to 130.

    Concerns

    2
    • Electrolyte additives segment is not expected to generate major revenues this year, with a maximum of ₹10-15 crores, due to current market conditions making commercial production uneconomical.

    • Pharma and agro combined contribution decreased to 46% (from previous higher levels), though management attributes this to timing shifts rather than degrowth.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue2,587 Mn+35%YoY
    2. 02EBITDA781 Mn+94%YoY
    3. 03EBITDA Margin30%
    4. 04PAT470 Mn+57.0%YoY
    5. 05PAT Margin18%

    Segment breakdown

    Business Model Contribution
    51% Large-Scale Manufacturing (LSM)37% Contract/Exclusive Manufacturing (CEM)10% Contract Research & Manufacturing Services (CRAMS)
    Sectoral Split
    46% Pharma & Agro19% Oil & Gas17% Material Science
    Geographical Split
    66% Domestic Sales33% Export Sales0.10-0.11 % of exports Europe0.04-0.05 % of exports China0.03-0.04 % of exports Japan0.05-0.06 % of exports US
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹350 crores

    Debt

    Debt disclosed

    Guidance & targets

    14
    CategoryTargetPriority
    Capacity
    Site 3+ (Milliken) Production Commencement
    Q4 FY26
    High
    Capacity
    Site 5 (Panoli) Production Blocks Commissioning
    End of Q3 FY26
    High
    Asset Turn
    Site 5 Asset Turn at Maturity
    1.75x
    High
    R&D Capacity
    Number of R&D Labs
    18
    High
    R&D Capacity
    Number of Fume Hoods
    130
    High
    Working Capital
    Working Capital Cycle
    165-170 days
    High
    Working Capital
    Working Capital Cycle
    150 days
    Medium
    Revenue
    Otsuka Chemicals Contract Revenue
    ₹35-40 crores
    Medium
    Revenue
    Electrolyte Additives Revenue
    ₹10-15 crores max
    High
    Contract Duration
    Milliken Contract Duration
    10 years
    High
    Commercialization Timeline
    CRAMS to CEM Conversion
    within 1 year
    High
    Site 5 Revenue
    LSM/CEM Revenue from Site 5
    good inflow
    Medium
    Market Size
    Addressable Market for Site 5 LSM Products
    ₹1,500 crores
    High
    Margin
    Milliken Contract Margin Profile
    similar or better than company average
    High

    What to watch in Q2 FY26

    5

    Site 3+ (Milliken) Production Commencement

    next quarter
    CurrentUnder construction, expected Q4 FY26
    TargetProgress towards Q4 FY26 commencement

    Why it matters

    Crucial for realizing revenue from the new 10-year Milliken contract and validating capex execution.

    Site 3+, which we have dedicated to Milliken is expected to commence production by quarter 4 of financial year 2026.

    Risks & concerns

    4
    RiskSeverity

    Geopolitical tensions and tariff uncertainties

    Last quarter was marked by heightened geopolitical tensions and tariff uncertainties, impacting the macro environment.Management acknowledged

    medium

    Soft economic environment

    Despite macro volatility or soft economic environment in recent months, client visits and project discussions have increased.Management acknowledged

    medium

    China dumping impacting LSM prices

    Prices in the LSM segment are still subdued because of Chinese dumping, though volume growth is observed.Management acknowledged

    medium

    Uneconomical commercial production of electrolyte additives

    Current electrolyte prices make commercial production uneconomical, leading to low revenue expectations (₹10-15 crores max) for the current year.Management acknowledged

    medium

    Q&A highlights

    8

    “Actually, the growth factor for contract manufacturing is the Baker, which has kicked in, which started from the last quarter slowly and then we have capitalized in that, and we have taken we have got a revenue of around INR410 million from them, and that is the driving force.”

    Clarifies the significant contribution of a key client (Baker Hughes) to CEM revenue growth this quarter.

    asked by Abhijit Akella

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Overview

    Aether Industries delivered a robust Q1 FY26, with total consolidated revenue growing 35% year-on-year to ₹2,587 million. EBITDA saw a significant increase of 94% YoY, reaching ₹781 million, leading to an expanded EBITDA margin of 30% compared to 22% in Q1 FY25. Profit After Tax (PAT) also surged by 57% YoY to ₹470 million, with the PAT margin improving to 18% from 16% in the prior year.

    02

    Large-Scale Manufacturing (LSM) and Contract Manufacturing (CEM) Growth

    The large-scale manufacturing (LSM) vertical demonstrated strong demand, growing 9% YoY and 8% QoQ, with the addition of six new clients. The company's business model mix saw 51% contribution from LSM, 37% from Contract/Exclusive Manufacturing (CEM), and 10% from Contract Research and Manufacturing Services (CRAMS). A significant portion of CEM growth was driven by Baker Hughes, contributing approximately ₹410 million in revenue this quarter, with supplies made to their Indian entity.

    03

    Strategic Expansions and Capacity Building

    Aether is on track with its capex plans, targeting ₹350 crores for FY26, allocated across R&D, Site 3++, and Site 5. The new Site 3+, dedicated to the Milliken contract, is expected to commence production by Q4 FY26. Site 5 in Panoli is progressing smoothly, with the first two production blocks targeted for commissioning by the end of Q3 FY26. The company also plans to expand its R&D facilities with a ₹30-40 crore investment, increasing labs from 15 to 18 and fume hoods from 65 to 130.

    04

    New Client Engagements and Contract Wins

    A significant milestone was the execution of a 10-year contract manufacturing agreement with Milliken Chemical & Textile India Company Private Limited, a wholly-owned subsidiary of USA-headquartered Milliken & Company. Aether will be the sole contract manufacturing partner for a key strategic product, dedicating its new Site 3+ for this purpose. Management noted that this new product for Milliken will be manufactured for the first time globally by Aether.

    05

    Sectoral Mix Evolution and Export Strategy

    The sectoral split for Q1 FY26 showed pharma and agro combined contributing 46%, while oil and gas contributed 19% and material science 17%. This shift aligns with the company's expectation for increased contributions from oil & gas and material science. Exports accounted for 33% of total revenues, with domestic sales at 66%, largely influenced by supplies to Baker Hughes' Indian entity. Key export geographies include Europe (10-11%), China (4-5%), Japan (3-4%), and the US (5-6%).

    06

    Working Capital Management and Debt Profile

    Aether successfully reduced its working capital cycle to 190 days from 195 days as of March 31, 2025, with inventory days decreasing to 165 from 175. The company aims to further reduce the working capital cycle to 165-170 days by the end of FY26 and to 150 days in the next 2-3 years. Management clarified that the company primarily utilizes short-term working capital debt and has no long-term debt, with internal accruals expected to fund future needs.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.